- Conditions
- Male Pattern Baldness, Female Pattern Baldness
- Interventions
- low-level laser/light therapy
- Device
- Lead sponsor
- Awareable Technologies Inc
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Ijamsville, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 673–696
of 17,649
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- Itacitinib, Everolimus
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Covid19
- Interventions
- Famotidine, N-Acetyl cysteine
- Drug
- Lead sponsor
- Prisma Health-Upstate
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Easley, South Carolina • Greenville, South Carolina • Greer, South Carolina
- Conditions
- Colorectal Cancer
- Interventions
- Irinotecan, capecitabine [Xeloda]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 10
- States / cities
- Hoover, Alabama • La Jolla, California • Miami, Florida + 7 more
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Insulin Dependent Diabetes, ALT
- Interventions
- Betaine (trimethyglycine)
- Dietary Supplement
- Lead sponsor
- Southern California Institute for Research and Education
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2025
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- Circadian Rhythm Sleep Disorders, Non-24 Hour Sleep-Wake Disorder, Autism Spectrum Disorder, Smith-Magenis Syndrome
- Interventions
- tasimelteon
- Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Multiple Myeloma
- Interventions
- Dexamethasone
- Drug
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Lamellar Ichthyosis, Congenital Ichthyosiform Erythroderma, Epidermolytic Ichthyosis, Netherton Syndrome
- Interventions
- Secukinumab, Placebo
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • New York, New York
- Conditions
- Ovarian Epithelial Carcinoma
- Interventions
- PD0332991
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Acute Kidney Injury
- Interventions
- CXA-10, pravastatin, Vytorin® (combination of simvastatin and ezetimibe)
- Drug
- Lead sponsor
- Complexa, Inc.
- Industry
- Eligibility
- 19 Years to 30 Years · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Kalamazoo, Michigan
- Conditions
- Melanoma
- Interventions
- Nivolumab, Ipilimumab, RO7247669 2100 mg, Atezolizumab, Tiragolumab, RO7247669 600 mg
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 4
- States / cities
- Duarte, California • Los Angeles, California • Tampa, Florida + 1 more
- Conditions
- Polycystic Kidney, Autosomal Dominant
- Interventions
- Tolvaptan
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,803 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 70 more
- Conditions
- Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma, Ocular Melanoma, Stage IIB Cutaneous Melanoma AJCC v6 and v7, Stage IIC Cutaneous Melanoma AJCC v6 and v7, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • New York, New York • Durham, North Carolina + 3 more
- Conditions
- Healthy
- Interventions
- Oral [14C]PF-07328948, Oral Unlabeled PF-07328948, IV [14C]PF-07328948
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Interventions
- Acthar Gel
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 8
- States / cities
- Clearwater, Florida • Indianapolis, Indiana • Waltham, Massachusetts + 5 more
- Conditions
- Autism Spectrum Disorder
- Interventions
- baclofen, intrathecal
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 10 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Obesity, Healthy Volunteers
- Interventions
- S309309, Itraconazole
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
- Interventions
- CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab
- Drug
- Lead sponsor
- CellCentric Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania
- Conditions
- Infection, Human Immunodeficiency Virus, HIV Infections
- Interventions
- GSK2248761 formulation 1, GSK2248761 reference formulation, GSK2248761 formulation 3, GSK2248761 formulation 2 or 4
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Opioid-Induced Constipation
- Interventions
- Methylnaltrexone bromide
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 26
- States / cities
- Mobile, Alabama • Laguna Hills, California • Lancaster, California + 20 more
- Conditions
- Schizophrenia, Pediatric
- Interventions
- Lumateperone 42 mg, Lumateperone 28 mg
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Hollywood, Florida • Atlanta, Georgia • Decatur, Georgia
- Conditions
- Suspected or Documented Gram-negative Bacterial Infection
- Interventions
- IMI/REL, Active Control, Oral Switch
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Long Beach, California • San Diego, California + 5 more
- Conditions
- Healthy Volunteers
- Interventions
- TAK-881
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Hialeah, Florida
- Conditions
- Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
- Interventions
- INZ-701
- Drug
- Lead sponsor
- Inozyme Pharma
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Eatontown, New Jersey